Literature DB >> 23618802

Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis.

Daniel Wendling1, Claire Vidon, Marie Godfrin-Valnet, Gilles Rival, Xavier Guillot, Clément Prati.   

Abstract

Entities:  

Keywords:  Interstitial lung disease; Pulmonary fibrosis; Rheumatoid arthritis; Tocilizumab

Mesh：

Substances：

Year:  2013        PMID： 23618802     DOI： 10.1016/j.jbspin.2013.03.009

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  12 in total

1.  Tocilizumab for refractory organising pneumonia associated with Sjögren's disease.

Authors:  Aurelien Justet; Sebastien Ottaviani; Philippe Dieudé; Camille Taillé
Journal:  BMJ Case Rep       Date:  2015-05-14

Review 2.  Treatment of rheumatoid arthritis-associated interstitial lung disease: a perspective review.

Authors:  Kundan Iqbal; Clive Kelly
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

Review 3.  Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD).

Authors:  Adelle S Jee; Tamera J Corte
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

4.  The value of blood cytokines and chemokines in assessing COPD.

Authors:  Eric Bradford; Sean Jacobson; Jason Varasteh; Alejandro P Comellas; Prescott Woodruff; Wanda O'Neal; Dawn L DeMeo; Xingnan Li; Victor Kim; Michael Cho; Peter J Castaldi; Craig Hersh; Edwin K Silverman; James D Crapo; Katerina Kechris; Russell P Bowler
Journal:  Respir Res       Date:  2017-10-24

Review 5.  Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.

Authors:  Andrea Picchianti Diamanti; Milica Markovic; Giuseppe Argento; Simonetta Giovagnoli; Alberto Ricci; Bruno Laganà; Raffaele D'Amelio
Journal:  Ther Adv Respir Dis       Date:  2016-10-12       Impact factor: 4.031

Review 6.  The safety of biologic therapies in RA-associated interstitial lung disease.

Authors:  Meghna Jani; Nik Hirani; Eric L Matteson; William G Dixon
Journal:  Nat Rev Rheumatol       Date:  2013-12-24       Impact factor: 20.543

Review 7.  Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis.

Authors:  Shunsuke Mori
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2015-09-08

8.  Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis.

Authors:  Takeshi Kobayashi; Kensuke Tanaka; Tetsuo Fujita; Hiroki Umezawa; Hiroyuki Amano; Kento Yoshioka; Yusuke Naito; Masahiko Hatano; Sadao Kimura; Koichiro Tatsumi; Yoshitoshi Kasuya
Journal:  Respir Res       Date:  2015-08-20

Review 9.  Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows.

Authors:  Giulia Cassone; Andreina Manfredi; Caterina Vacchi; Fabrizio Luppi; Francesca Coppi; Carlo Salvarani; Marco Sebastiani
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

10.  IL-17A+GM-CSF+ Neutrophils Are the Major Infiltrating Cells in Interstitial Lung Disease in an Autoimmune Arthritis Model.

Authors:  Oh Chan Kwon; Eun-Ju Lee; Eun-Ju Chang; Jeehee Youn; Byeongzu Ghang; Seokchan Hong; Chang-Keun Lee; Bin Yoo; Yong-Gil Kim
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.